BERLIN & NEVADA--(BUSINESS WIRE)--MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced that the Department of Neurosurgery at Kiel University Hospital (UKSH), headed by Professor Dr. Hubertus Maximilian Mehdorn, has initiated NanoTherm(TM) therapy in the commercial setting for the treatment of brain cancers.
After the start of commercial treatments of brain cancers at the University Hospital in Munster in February, this marks another milestone for MagForce with now two world class medical centers offering NanoTherm(TM) therapy also in the commercial setting.
Help employers find you! Check out all the jobs and post your resume.
